eltrombopag

Also known as ETB115, AMG531, SB-497115-GR, 3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid

Eltrombopag, sold under the brand name Promacta among others, is a medication used to treat thrombocytopenia (abnormally low platelet counts) and severe aplastic anemia. Eltrombopag is sold under the brand name Revolade outside the US and is marketed by Novartis. It is a thrombopoietin receptor agonist. It is taken by mouth.

In the Vinony graph

Vinony's link graph records 266 inbound references to eltrombopag, and connects out to GSK, influenza vaccine and meningococcal vaccine.

It sits within the topics Biphenyls, Carboxylic acids and Chemical articles with multiple CAS registry numbers.

Vinony links it to 13 Wikipedia language editions.

Key facts

Drug.Verifiedfields: changed
Drug.Watchedfields: changed
Drug.verifiedrevid: 461093150
Drug.image: eltrombopag.svg
Drug.image_class: skin-invert-image
Drug.width: 270
Drug.tradename: Promacta, Revolade, others
Drug.MedlinePlus: a609011
Drug.DailyMedID: Eltrombopag olamine
Drug.pregnancy_AU: B3
Drug.routes_of_administration: By mouth
Drug.ATC_prefix: B02
Drug.ATC_suffix: BX05
Drug.legal_AU: S4
Drug.legal_UK: POM
Drug.legal_US: Rx-only
Drug.legal_EU: Rx-only
Drug.bioavailability: ~52%

via Wikipedia infobox

Chemical data

Formula: C25H22N4O4
Molecular weight: 442.5 g/mol
IUPAC name: 3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acid
SMILES: CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C
InChIKey: SVOQIEJWJCQGDQ-UHFFFAOYSA-N
XLogP: 5.4
Polar surface area: 115 Å²
H-bond donors: 3
H-bond acceptors: 7
Formal charge: 0

via PubChem

Drug data · ChEMBL

Max clinical phase: Approved
Molecule type: Small molecule
First approval: 2008
Admin. routes: oral
Indications: hemorrhage, autoimmune thrombocytopenic purpura, liver disease, Thrombocytopenia

via ChEMBL · EBI

Research

1,602 papers

Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.The New England journal of medicine · 2017
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.Lancet (London, England) · 2011
Eltrombopag.Cancer treatment and research · 2011
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2021

via PubMed

Wikidata facts

Subclass of: carboxylic acid
Mass: 442.1641
Has use: medication

Show 8 more facts

chemical formula: C₂₅H₂₂N₄O₄
medical condition treated: thrombocytopenia
World Health Organisation international non-proprietary name: eltrombopag
isomeric SMILES: CC1=CC=C(C=C1C)N2C(=O)/C(=N\NC3=CC=CC(=C3O)C4=CC=CC(=C4)C(=O)O)/C(=N2)C
canonical SMILES: CC1=CC=C(C=C1C)N2C(=O)C(=NNC3=CC=CC(=C3O)C4=CC=CC(=C4)C(=O)O)C(=N2)C
defined daily dose: 50
significant drug interaction: simvastatin
Commons category: Eltrombopag

Sources (5)

via Wikidata · CC0

~6 min read

Encyclopedic overview

9 sections

Contents

Medical uses
Development
Clinical trials
History
Society and culture
Legal status
Research
References
External links

{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 461093150 | image = eltrombopag.svg | image_class = skin-invert-image | width = 270 | alt = | caption =

Excerpted from Wikipedia’s “eltrombopag” article, available under the CC BY-SA 4.0 licence.